Agafonova Nataliya 4

What Happened
Nataliya Agafonova, Chief Medical Officer of Longeveron, was granted 250,000 restricted stock units (RSUs) on 2026-05-01. The award is reported at $0.00 per share (a grant/compensation award rather than an open‑market purchase or sale). This is an acquisition-by-award (Form 4 transaction code A) reflecting a compensation grant, not an immediate cash transaction.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-05 (Accession: 0001214659-26-005618).
• Transaction type/code: Award/Grant (A).
• Shares granted: 250,000 RSUs; reported price: $0.00; reported cash value: $0.
• Shares owned after transaction: not specified in the supplied filing details.
• Footnotes: F1 — represents time‑based vesting RSUs; F2 — includes RSUs subject to future vesting.
• No late-filing flag was indicated in the provided summary.

Context
RSUs are a form of equity compensation that convert into actual shares only if and when vesting conditions are met (here, time‑based vesting per the filing footnote). Because these are awards rather than purchases or sales, they represent compensation alignment rather than an immediate insider bet on the stock price. The ultimate value realized by the insider will depend on the vesting schedule and Longeveron’s future share price.